Literature DB >> 21074377

Adverse events associated with intravenous fosfomycin.

Amélie Florent, Rose-Marie Chichmanian, Eric Cua, Céline Pulcini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21074377     DOI： 10.1016/j.ijantimicag.2010.09.002

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  17 in total

1.  Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Authors:  E Wenzler; E J Ellis-Grosse; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.

Authors:  Miao Zhao; Zackery P Bulman; Justin R Lenhard; Michael J Satlin; Barry N Kreiswirth; Thomas J Walsh; Amanda Marrocco; Phillip J Bergen; Roger L Nation; Jian Li; Jing Zhang; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

Review 3.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

Review 4.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

Review 5.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

Review 6.  Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Authors:  Moritz Fritzenwanker; Can Imirzalioglu; Susanne Herold; Florian M Wagenlehner; Klaus-Peter Zimmer; Trinad Chakraborty
Journal:  Dtsch Arztebl Int       Date:  2018-05-21       Impact factor: 5.594

7.  Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction.

Authors:  Matteo Rinaldi; Pier Giorgio Cojutti; Eleonora Zamparini; Sara Tedeschi; Nicolò Rossi; Matteo Conti; Maddalena Giannella; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

8.  Population Pharmacokinetics of Fosfomycin in Critically Ill Patients.

Authors:  Suzanne L Parker; Frantzeska Frantzeskaki; Steven C Wallis; Chryssa Diakaki; Helen Giamarellou; Despoina Koulenti; Ilias Karaiskos; Jeffrey Lipman; George Dimopoulos; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

Review 9.  Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Haley J Morrill; Jason M Pogue; Keith S Kaye; Kerry L LaPlante
Journal:  Open Forum Infect Dis       Date:  2015-05-05       Impact factor: 3.835

Review 10.  Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.

Authors:  Ilias Karaiskos; Helen Giamarellou
Journal:  Expert Opin Pharmacother       Date:  2014-04-28       Impact factor: 3.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.